The intermediate dose of (0.5–0.7 Gy) used in RT was also shown to reduce inflammatory and degenerative diseases [277,278] involving the expression of the X-linked inhibitor of apoptosis (XIAP) and TGFβ1 as well as reduction B and L-selectin and, also, secretion of the cytokine IL-1β or chemokine CCL20. The gene discussed is XIAP; the disease is neurodegenerative disease.